Our Pipeline

The Kiniksa pipeline has the potential to treat a spectrum of autoinflammatory & autoimmune diseases.

Program & Target	Indication	Preclin	Rights
RilonaceptIL-1α & IL-1β	Recurrent Pericarditis	Phase 3	Worldwide (excl. Middle East and North Africa)
MavrilimumabGM-CSFRα	Giant Cell Arteritis	Phase 2	Worldwide
KPL-716OSMRβ	Prurigo Nodularis	Phase 2	Worldwide
	Multi-indication Pilot Study in Diseases with a Chronic Pruritic Component	End Phase 1	Worldwide
	Atopic Dermatitis	Phase 1	Worldwide
KPL-045CD30L	T-cell dependent, B-cell-mediated indications	Preclin	Worldwide
KPL-404CD40	T-cell dependent, B-cell-mediated indications	Preclin	Worldwide

About Rilonacept

Rilonacept is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of IL-1α and IL-1β, two soluble cytokines. There are multiple diseases involving these cytokines where rilonacept may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies. We are currently enrolling RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis.

Mavrilimumab

Monoclonal antibody inhibitor of GM-CSF signaling. Currently enrolling a global Phase 2 study in Giant Cell Arteritis - an inflammatory disease of blood vessels with unmet need.

KPL-716

Monoclonal antibody inhibitor of both IL-31 and Oncostatin M, cytokines involved in pruritus, Th2 response, fibrosis and barrier dysfunction.

KPL-045

Monoclonal antibody inhibitor of a T-cell co-stimulatory mechanism important in the function of activated T-memory cells.

KPL-404